Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Mastocytosis, Systemic 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NIH × sarilumab × Clear all
NCT03770273 2024-12-17

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 13 charts
Myeloid

Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡